In recent years, the incidence of allergic asthma has increased dramatically. Allergen immunotherapy (AIT) is an effective approach to achieve long-term remission of allergic asthma and has gained widespread attention. However, current AIT suffers from low efficacy and long treatment duration. In this study, we found that IL-37a transgenic mice with allergic asthma exhibited reduced pulmonary inflammation, decreased Th2 cytokines, and lower allergen-specific IgE following AIT. Mechanistic studies revealed increased IL-37 + Bregs, suggesting that IL-37a may promote AIT through Bregs. Our study demonstrates the promoting effect of IL-37 in allergen immunotherapy and suggests that Bregs may underlie this mechanism, providing insights for overcoming the limitations of AIT in the future.
Jin et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: